February 7, 2005 -- Two weeks ago, the market hit its lowest point of the year by sliding 2.7% or 89 points to 3230. Since then, the Centient Biotech 200 has rallied an impressive 7.4% or 240 points and that is including today’s fairly minor loss. In today’s trading, the final figures on the CBT 200 show a loss of 12.08 points (.35%) to 3470.34. In individual stocks, Allergan guided lower and the stock followed suit, Axonyx took a clobbering after its Alzheimer’s drug failed a Phase III trial, InterMune lost ground after guiding lower, Vicuron moved up on news of a positive trial for its fungal infection drug, and Biosite leased 50 diagnostic targets from Incyte. We give more details...
